| 2 | National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial. (Cohen LN, Rogers CC, Lloren JIC, Kamaraju S, Chaudhary LN, Huang CC, Cobb AN, Singh P, Kong AL, Teshome M, Cortina CS) Breast Cancer Res Treat 2025 Jun 03 |
| 1 | Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer. (Tau S, Chamberlin MD, Yang H, Marotti JD, Muskus PC, Roberts AM, Carmichael MM, Cressey L, Dragnev CPC, Demidenko E, Hampsch RA, Soucy SM, Kolling FW, Samkoe KS, Alvarez JV, Kettenbach AN, Miller TW) Cancer Res 2025 Mar 14;85(6):1145-1161 |
| 1 | Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. (Cloyd JM, Sarna A, Arango MJ, Bates SE, Bhutani MS, Bloomston M, Chung V, Dotan E, Ferrone CR, Gambino PF, Goenka AH, Goodman KA, Hall WA, He J, Hogg ME, Jayaraman S, Kambadakone A, Katz MHG, Khorana AA, Ko AH, Koay EJ, Kooby DA, Krishna SG, Larsson LK, Lee RT, Maitra A, Massarweh NN, Mikhail S, Muzaffar M, O'Reilly EM, Palta M, Petzel MQB, Philip PA, Reyngold M, Santa Mina D, Sohal DPS, Sundaresan TK, Tsai S, Turner KL, Vreeland TJ, Walston S, Washington MK, Williams TM, Wo JY, Snyder RA) JAMA Surg 2025 Feb 01;160(2):172-180 3 Citations |
| 1 | Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. (Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS, NIAGARA Investigators) N Engl J Med 2024 Nov 14;391(19):1773-1786 65 Citations |
| 1 | Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience. (Krishnan J, Patel A, Roy AM, Alharbi M, Kapoor A, Yao S, Khoury T, Hong CC, Held N, Chakraborty A, Kaliniski P, Salman A, Catalfamo K, Attwood K, Kirtani V, Shaikh SS, Chaudhary LN, Gandhi S) Clin Breast Cancer 2024 Dec;24(8):e701-e711.e2 3 Citations |
| 8 | Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. (Beltran Ponce SE, Small CJ, Ahmad T, Patel K, Tsai S, Kamgar M, George B, Kharofa JR, Saeed H, Dua KS, Clarke CN, Aldakkak M, Evans DB, Christians K, Paulson ES, Erickson B, Hall WA) Pract Radiat Oncol 2025;15(1):e47-e56 |
| 1 | Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study. (Kastenberg ZJ, Short SS, Riehle KJ, Utria A, Lautz TB, Ott KC, Murphy AJ, Mansfield S, Lal DR, Hallis B, Murphy JT, Roach JP, Polites SF, Beckhorn C, Tracy ET, Fialkowski EA, Seemann NM, Bütter AM, Rich BS, Glick RD, Bondoc AJ, Ofori-Atta BS, Presson AP, Chen SY, Zamora AK, Kim ES, Vasudevan S, Rinehardt HN, Malek MM, Lapidus-Krol E, Putra J, Superina RA, Langham MR, Meyers RL, Tiao G, Dasgupta R, Baertschiger R) Pediatr Blood Cancer 2024 Jun;71(6):e30975 3 Citations |
| 1 | ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer. (Cortina CS, Rogers CC, Teshome M) Ann Surg Oncol 2024 May;31(5):3196-3197 2 Citations |
| 6 | Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. (George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S) Gastroenterology 2024 May;166(5):859-871.e3 12 Citations |
| 3 | Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery? (Cortina CS, Lloren JI, Rogers C, Johnson MK, Cobb AN, Huang CC, Kong AL, Singh P, Teshome M) Ann Surg Oncol 2024 May;31(5):3128-3140 4 Citations |
| 4 | National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. (Rogers C, Cobb AN, Lloren JIC, Chaudhary LN, Johnson MK, Huang CC, Teshome M, Kong AL, Singh P, Cortina CS) Breast Cancer Res Treat 2024 Jan;203(2):317-328 10 Citations |
| 1 | Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. (Badgery HE, Muhlen-Schulte T, Zalcberg JR, D'souza B, Gerstenmaier JF, Pickett C, Samra J, Croagh D, Pancreatic Cancer Image Biobank Authorship Group) HPB (Oxford) 2023 Nov;25(11):1393-1401 8 Citations |
| 1 | Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma. (Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, dePrisco G, Yothers G, Dorth JA, Rahma OE, Russell MM, Gross HM, Jacobs SA, Faller BA, George S, Al Baghdadi T, Haddock MG, Valicenti R, Hong TS, George TJ) J Clin Oncol 2023 Oct 10;41(29):4643-4651 16 Citations |
| 7 | Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy. (Chaudhary LN, Jorns JM, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo MB, Kong AL, Patten C, Yen T, Cortina CS, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H) Breast Cancer Res Treat 2023 Oct;201(3):387-396 7 Citations |
| 9 | Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. (Thalji SZ, Fernando D, Dua KS, Madhavan S, Chisholm P, Smith ZL, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Evans DB, Tsai S) Ann Surg 2023 Dec 01;278(6):e1224-e1231 3 Citations |
| 1 | Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. (Wang D, Harris J, Kraybill WG, Eisenberg B, Kirsch DG, Ettinger DS, Kane JM 3rd, Barry PN, Naghavi A, Freeman CR, Chen YL, Hitchcock YJ, Bedi M, Salerno KE, Severin D, Godette KD, Larrier NA, Curran WJ Jr, Torres-Saavedra PA, Lucas DR) JAMA Oncol 2023 May 01;9(5):646-655 25 Citations |
| 3 | Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. (Thalji SZ, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Chisholm P, Kulkarni N, Doucette S, Evans DB, Tsai S) J Surg Oncol 2023 Jul;128(1):41-50 3 Citations |
| 5 | CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S) Ann Surg Oncol 2023 May;30(5):3013-3021 7 Citations |
| 2 | Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. (Hall WA, Evans DB, Tsai S) JAMA Oncol 2023 Feb 01;9(2):275-276 2 Citations |
| 3 | A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma. (Saif A, Verbus E, Erickson B, Kamgar M, Tsai S, Evans D, Hernandez JM, Hall WA) Ann Surg Oncol 2023 Feb;30(2):688-690 2 Citations |
| 1 | Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. (Hammad AY, Hodges JC, AlMasri S, Paniccia A, Lee KK, Bahary N, Singhi AD, Ellsworth SG, Aldakkak M, Evans DB, Tsai S, Zureikat A) JAMA Surg 2023 Jan 01;158(1):55-62 19 Citations |
| 3 | Predicting Neoadjuvant Treatment Response in Rectal Cancer Using Machine Learning: Evaluation of MRI-Based Radiomic and Clinical Models. (Peterson KJ, Simpson MT, Drezdzon MK, Szabo A, Ausman RA, Nencka AS, Knechtges PM, Peterson CY, Ludwig KA, Ridolfi TJ) J Gastrointest Surg 2023 Jan;27(1):122-130 7 Citations |
| 1 | Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. (Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX) Ann Surg Oncol 2022 Oct;29(10):6381-6392 3 Citations |
| 1 | Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. (O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A) Gynecol Oncol 2022 Jul;166(1):36-43 21 Citations |
| 1 | Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. (Kelly KN, Macedo FI, Seaton M, Wilson G, Hammill C, Martin RC, Maduekwe UN, Kim HJ, Maithel SK, Abbott DE, Ahmad SA, Kooby DA, Merchant NB, Datta J) Ann Surg Oncol 2022 Sep;29(9):6004-6012 8 Citations |
| 1 | Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. (Samson A, West EJ, Carmichael J, Scott KJ, Turnbull S, Kuszlewicz B, Dave RV, Peckham-Cooper A, Tidswell E, Kingston J, Johnpulle M, da Silva B, Jennings VA, Bendjama K, Stojkowitz N, Lusky M, Prasad KR, Toogood GJ, Auer R, Bell J, Twelves CJ, Harrington KJ, Vile RG, Pandha H, Errington-Mais F, Ralph C, Newton DJ, Anthoney A, Melcher AA, Collinson F) Cancer Immunol Res 2022 Jun 03;10(6):745-756 29 Citations |
| 1 | Outcomes of Mixed Pathologic Response in Patients with Multiple Colorectal Liver Metastases Treated with Neoadjuvant Chemotherapy and Liver Resection. (Mason MC, Krasnodebski M, Hester CA, Kothari AN, Barker C, Nishioka Y, Chiang YJ, Newhook TE, Tzeng CD, Chun YS, Vauthey JN, Tran Cao HS) Ann Surg Oncol 2022 Aug;29(8):5156-5164 6 Citations |
| 1 | Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. (Goff PH, Riolobos L, LaFleur BJ, Spraker MB, Seo YD, Smythe KS, Campbell JS, Pierce RH, Zhang Y, He Q, Kim EY, Schaub SK, Kane GM, Mantilla JG, Chen EY, Ricciotti R, Thompson MJ, Cranmer LD, Wagner MJ, Loggers ET, Jones RL, Murphy E, Blumenschein WM, McClanahan TK, Earls J, Flanagan KC, LaFranzo NA, Kim TS, Pollack SM) Clin Cancer Res 2022 Apr 14;28(8):1701-1711 27 Citations |
| 2 | Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. (Hall WA, Erickson B, Crane CH) Surg Oncol Clin N Am 2021 Oct;30(4):719-730 5 Citations |
| 1 | GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. (Thaker PH, Bradley WH, Leath CA 3rd, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD) Clin Cancer Res 2021 Oct 15;27(20):5536-5545 20 Citations |
| 1 | Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. (Salerno KE, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, Chung P, DeLaney TF, Folpe A, Kane JM, Li XA, Petersen I, Powell J, Stolten M, Thorpe S, Trent JC, Voermans M, Guadagnolo BA) Pract Radiat Oncol 2021;11(5):339-351 112 Citations |
| 1 | Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. (Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, George S, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ) JAMA Oncol 2021 Aug 01;7(8):1225-1230 139 Citations |
| 1 | HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update. (Wang L, Asirvatham JR, Ma Y, Reisenbichler ES, Jorns JM) Breast J 2021 Aug;27(8):631-637 6 Citations |
| 1 | Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. (Ward EP, Evans DB, Tsai S) J Surg Oncol 2021 May;123(6):1405-1413 4 Citations |
| 1 | Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. (Mahadevan A, Moningi S, Grimm J, Li XA, Forster KM, Palta M, Prior P, Goodman KA, Narang A, Heron DE, Lo SS, Urbanic J, Herman JM) Int J Radiat Oncol Biol Phys 2021 May 01;110(1):206-216 34 Citations |
| 3 | Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. (Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, Evans DB, Tsai S) Am J Surg 2021 Jul;222(1):10-17 66 Citations |
| 3 | Total Neoadjuvant Therapy for Operable Pancreatic Cancer. (Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S) Ann Surg Oncol 2021 Apr;28(4):2246-2256 40 Citations |
| 1 | Is Breast Magnetic Resonance Imaging an Accurate Predictor of Nodal Status After Neoadjuvant Chemotherapy? (Cortina CS, Gottschalk N, Kulkarni SA, Karst I) J Surg Res 2021 Jan;257:412-418 5 Citations |
| 1 | Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy. (Evans DB) Surgery 2021 May;169(5):1032-1033 4 Citations |
| 1 | Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. (Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM) Clin Cancer Res 2020 Nov 01;26(21):5668-5681 45 Citations |
| 1 | The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505. (Evans DB) Ann Surg 2020 Sep 01;272(3):487 13 Citations |
| 7 | Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. (Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S) Surgery 2020 Sep;168(3):440-447 16 Citations |
| 1 | Early stage triple negative breast cancer: Management and future directions. (Chaudhary LN) Semin Oncol 2020 Aug;47(4):201-208 34 Citations |
| 1 | AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells. (Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW) Clin Cancer Res 2020 Jul 15;26(14):3707-3719 66 Citations |
| 2 | Neoadjuvant radiation improves margin-negative resection rates in extremity sarcoma but not survival. (Shelby RD, Suarez-Kelly LP, Yu PY, Hughes TM, Ethun CG, Tran TB, Poultsides G, King DM, Bedi M, Mogal H, Clarke C, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick BA, Fields RC, Pollock RE, Howard JH, Cardona K, Grignol V) J Surg Oncol 2020 Jun;121(8):1249-1258 9 Citations |
| 2 | Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. (Rowan DJ, Hartley CP, Aldakkak M, Christians KK, Evans DB, Tsai S, Hagen CE) Ann Diagn Pathol 2020 Jun;46:151485 8 Citations |
| 3 | Is a Nomogram Able to Predict Postoperative Wound Complications in Localized Soft-tissue Sarcomas of the Extremity? (Bedi M, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Cullinan D, Fields RC, Cardona K, King DM) Clin Orthop Relat Res 2020 Mar;478(3):550-559 17 Citations |
| 3 | A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology. (Arispe Angulo KR, Jawa Z, Visotcky A, Majidi SS, Chitambar CR, Jorns JM) Histopathology 2020 Apr;76(5):661-670 2 Citations |
| 2 | Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? (Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S) J Gastrointest Surg 2020 Feb;24(2):235-242 10 Citations |
| 4 | Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. (Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W, Erickson B, Evans DB, Tsai S) Ann Surg Oncol 2019 Dec;26(13):4515-4521 7 Citations |
| 2 | Goals of Treatment Sequencing for Localized Pancreatic Cancer. (Evans DB, Kamgar M, Tsai S) Ann Surg Oncol 2019 Nov;26(12):3815-3819 6 Citations |
| 6 | Use of Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer. (Hu KY, Simpson MT, Blank JJ, Szabo A, Eastwood D, Ludwig KA, Peterson CY, Ridolfi TJ) J Surg Res 2019 Nov;243:447-452 11 Citations |
| 1 | Treatment of Hepatocellular Carcinoma: Time for a Paradigm Shift? (White SB) Radiology 2019 Sep;292(3):760-761 2 Citations |
| 1 | Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review. (Chae YK, Saleem N, Roh Y, Bilal H, Viveiros P, Sukhadia B, Lin X, Sheikh MM, Park LC) BMC Cancer 2019 Jul 30;19(1):748 6 Citations |
| 1 | Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. (Zaidi MY, Ethun CG, Tran TB, Poultsides G, Grignol VP, Howard JH, Bedi M, Mogal H, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick B, Fields RC, Oskouei S, Reimer N, Monson D, Maithel SK, Cardona K) Ann Surg Oncol 2019 Oct;26(11):3542-3549 20 Citations |
| 1 | Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. (Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, Ahmad SA, Patel SH, Abbott DE, Schwartz P, Weber SM, Scoggins CR, Martin RCG, Dudeja V, Franceschi D, Livingstone AS, Merchant NB) Ann Surg 2019 Sep;270(3):400-413 138 Citations |
| 1 | Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. (Seo DW, Sherman S, Dua KS, Slivka A, Roy A, Costamagna G, Deviere J, Peetermans J, Rousseau M, Nakai Y, Isayama H, Kozarek R, Biliary SEMS During Neoadjuvant Therapy Study Group) Gastrointest Endosc 2019 Oct;90(4):602-612.e4 84 Citations |
| 6 | Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. (Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK) Surgery 2019 Sep;166(3):277-285 50 Citations |
| 3 | The role of radiation therapy and margin width in localized soft-tissue sarcoma: Analysis from the US Sarcoma Collaborative. (Gannon NP, King DM, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Votanopoulos K, Krasnick B, Fields RC, Cardona K, Bedi M) J Surg Oncol 2019 Sep;120(3):325-331 19 Citations |
| 2 | Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. (Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hong JC) J Surg Res 2019 Oct;242:23-30 27 Citations |
| 1 | Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. (Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM) Int J Radiat Oncol Biol Phys 2019 Aug 01;104(5):1057-1065 11 Citations |
| 2 | Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma. (Gannon NP, Stemm MH, King DM, Bedi M) J Cancer Res Clin Oncol 2019 May;145(5):1321-1330 28 Citations |
| 3 | Does Vacuum-assisted Closure Reduce the Risk of Wound Complications in Patients With Lower Extremity Sarcomas Treated With Preoperative Radiation? (Bedi M, King DM, DeVries J, Hackbarth DA, Neilson JC) Clin Orthop Relat Res 2019 Apr;477(4):768-774 31 Citations |
| 1 | Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS. (Istl AC, Ruck JM, Morris CD, Levin AS, Meyer CF, Johnston FM) J Surg Oncol 2019 Jun;119(7):824-835 14 Citations |
| 2 | Patient selection in studies evaluating esophageal stents during neoadjuvant therapy. (Smith ZL, Dua KS) Gastrointest Endosc 2019 Jan;89(1):205-206 2 Citations |
| 1 | Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. (Kim BJ, Prakash L, Narula N, Davis CH, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MH, Tzeng CD) HPB (Oxford) 2019 Jun;21(6):662-668 10 Citations |
| 1 | State of the art: Rehabilitation of speech and swallowing after total laryngectomy. (Zenga J, Goldsmith T, Bunting G, Deschler DG) Oral Oncol 2018 Nov;86:38-47 65 Citations |
| 1 | Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery. (McCool KW, Sampene E, Polnaszek B, Connor J, Medlin EE, Barroilhet L) BMC Cancer 2018 Oct 26;18(1):1041 6 Citations |
| 4 | Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. (Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB) Ann Surg 2020 Apr;271(4):740-747 149 Citations |
| 3 | Management of the axilla after neo-adjuvant chemotherapy for breast cancer: Sentinel node biopsy and radiotherapy considerations. (Currey A, Patten CR, Bergom C, Wilson JF, Kong AL) Breast J 2018 Nov;24(6):902-910 10 Citations |
| 4 | A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. (Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB) Ann Surg 2018 Oct;268(4):610-619 67 Citations |
| 1 | Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. (Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA) J Transl Med 2018 Jul 04;16(1):184 44 Citations |
| 6 | Postoperative Day 1 Glucose May Be Associated With Wound Complications in Sarcomas Treated With Preoperative Radiation. (Bedi M, King DM, Mendez C, Slawski B, Charlson JA, Hackbarth DA, Neilson JC) Clin Orthop Relat Res 2018 Mar;476(3):580-586 1 Citation |
| 1 | Neoadjuvant Radiation Is Associated with Fistula Formation Following Pancreaticoduodenectomy. (Zettervall SL, Ju T, Holzmacher JL, Rivas L, Lin PP, Vaziri K) J Gastrointest Surg 2018 Jun;22(6):1026-1033 10 Citations |
| 5 | Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. (Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN) JAMA Oncol 2018 Mar 01;4(3):343-350 133 Citations |
| 1 | Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment. (Qu LT, Peters S, Cobb AN, Godellas CV, Perez CB, Vaince FT) Am J Surg 2018 Mar;215(3):530-533 6 Citations |
| 5 | Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. (Bhalla M, Aldakkak M, Kulkarni NM, O'Connor SD, Griffin MO Jr, Christians KK, Evans DB, Tsai S, Tolat PP) Abdom Radiol (NY) 2018 Feb;43(2):351-363 12 Citations |
| 1 | Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. (Delitto D, George TJ Jr, Loftus TJ, Qiu P, Chang GJ, Allegra CJ, Hall WA, Hughes SJ, Tan SA, Shaw CM, Iqbal A) J Natl Cancer Inst 2018 May 01;110(5):460-466 18 Citations |
| 1 | Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? (Chaudhary LN, Wilkinson KH, Kong A) Surg Oncol Clin N Am 2018 Jan;27(1):141-153 129 Citations |
| 3 | Self-Expanding Metal Stents Improve Swallowing and Maintain Nutrition During Neoadjuvant Therapy for Esophageal Cancer. (Smith ZL, Gonzaga JE, Haasler GB, Gore EM, Dua KS) Dig Dis Sci 2017 Jun;62(6):1647-1656 9 Citations |
| 1 | Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. (Tevaarwerk AJ, Hocking WG, Zeal JL, Gribble M, Seaborne L, Buhr KA, Wisinski KB, Burkard ME, Wiegmann DA, Sesto ME) J Oncol Pract 2017 May;13(5):e486-e495 16 Citations |
| 3 | Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. (Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, Foley WD, Aburajab M, Evans DB, Tsai S) J Gastrointest Surg 2017 Mar;21(3):496-505 10 Citations |
| 1 | Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer. (Wang Y, Mark KM, Ung MH, Kettenbach A, Miller T, Xu W, Cheng W, Xia T, Cheng C) Genome Med 2016 Oct 27;8(1):114 3 Citations |
| 1 | Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. (Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE) J Gastrointest Surg 2017 Jan;21(1):164-174 124 Citations |
| 4 | Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? (Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S) J Surg Oncol 2016 Oct;114(5):581-586 26 Citations |
| 3 | Evolution of the Management of Resectable Pancreatic Cancer. (Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB) J Oncol Pract 2016 Sep;12(9):772-8 24 Citations |
| 1 | Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. (de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC, Tseng JF) Eur J Surg Oncol 2016 Oct;42(10):1552-60 51 Citations |
| 1 | Therapeutic Advances in Localized Pancreatic Cancer. (Tsai S, Evans DB) JAMA Surg 2016 Sep 01;151(9):862-8 53 Citations |
| 3 | Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. (Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S) J Surg Oncol 2016 Sep;114(3):291-5 17 Citations |
| 1 | Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. (Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES) PLoS One 2016;11(5):e0155503 6 Citations |
| 1 | Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. (O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF) Clin Genitourin Cancer 2016 Dec;14(6):511-517 5 Citations |
| 1 | Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review. (Cheng H, Miura JT, Lalehzari M, Rajeev R, Donahue AE, Bedi M, Gamblin TC, Turaga KK, Johnston FM) J Surg Oncol 2016 May;113(6):628-34 26 Citations |
| 1 | Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. (Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES) Anticancer Res 2016 Feb;36(2):495-501 47 Citations |
| 4 | Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. (Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S) Surgery 2016 Mar;159(3):893-900 105 Citations |
| 2 | Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. (Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, Zanville NR, Champion VL, Schneider BP, Saykin AJ) J Clin Oncol 2016 Mar 01;34(7):677-83 45 Citations |
| 4 | Biopsies in the Community Lead to Postoperative Complications in Soft Tissue Sarcomas. (Bedi M, King DM, Hackbarth DA, Charlson JA, Baynes K, Neilson JC) Orthopedics 2015 Sep;38(9):e753-9 4 Citations |
| 3 | Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. (Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S) HPB (Oxford) 2015 Oct;17(10):942-52 55 Citations |
| 3 | Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. (Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S) Surgery 2015 Dec;158(6):1545-55 31 Citations |
| 1 | A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. (Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, Suardi N, Briganti A, Montorsi F, Cathelineau X) World J Urol 2016 Feb;34(2):207-13 16 Citations |
| 1 | Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy. (Evans DB, George B, Tsai S) Ann Surg Oncol 2015 Oct;22(11):3409-13 71 Citations |
| 1 | Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. (Rodrigues G, Choy H, Bradley J, Rosenzweig KE, Bogart J, Curran WJ Jr, Gore E, Langer C, Louie AV, Lutz S, Machtay M, Puri V, Werner-Wasik M, Videtic GMM) Pract Radiat Oncol 2015;5(3):149-155 45 Citations |
| 1 | Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial. (Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, Petersen IA, DeLaney TF, Freeman CR, Finkelstein SE, Hitchcock YJ, Bedi M, Singh AK, Dundas G, Kirsch DG) J Clin Oncol 2015 Jul 10;33(20):2231-8 224 Citations |
| 2 | Neoadjuvant therapy for localized pancreatic cancer: support is growing? (Evans DB, Ritch PS, Erickson BA) Ann Surg 2015 Jan;261(1):18-20 19 Citations |
| 1 | Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. (Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH) Ann Surg Oncol 2015 Jul;22(7):2416-23 132 Citations |
| 4 | Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. (Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B) Radiother Oncol 2014 Oct;113(1):41-6 44 Citations |
| 2 | Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 32 Citations |
| 3 | Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. (Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK) HPB (Oxford) 2015 Feb;17(2):131-9 19 Citations |
| 1 | Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis. (Pandanaboyana S, White A, Pathak S, Hidalgo EL, Toogood G, Lodge JP, Prasad KR) Ann Surg Oncol 2015 Jan;22(1):173-9 32 Citations |
| 1 | Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. (Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH) Lung Cancer 2014 Jul;85(1):88-93 73 Citations |
| 1 | Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. (Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG) World J Surg 2014 Jun;38(6):1318-27 51 Citations |
| 1 | Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance. (Cho H, Cho CS, Indig GL, Lavasanifar A, Vakili MR, Kwon GS) PLoS One 2014;9(2):e89968 16 Citations |
| 5 | Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 175 Citations |
| 1 | Neoadjuvant chemotherapy for localized pancreatic cancer: too little or too long? (White RR, Evans DB) Ann Surg Oncol 2014 May;21(5):1508-9 1 Citation |
| 1 | Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. (Morris-Stiff G, White AD, Gomez D, Cameron IC, Farid S, Toogood GJ, Lodge JP, Prasad KR) Eur J Surg Oncol 2014 Aug;40(8):1016-20 31 Citations |
| 1 | Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. (Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH) J Gastrointest Surg 2014 Jan;18(1):16-24; discussion 24-5 172 Citations |
| 1 | Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. (Tran Cao HS, Balachandran A, Wang H, Nogueras-González GM, Bailey CE, Lee JE, Pisters PW, Evans DB, Varadhachary G, Crane CH, Aloia TA, Vauthey JN, Fleming JB, Katz MH) J Gastrointest Surg 2014 Feb;18(2):269-78; discussion 278 108 Citations |
| 1 | Repeat liver resection after a hepatic or extended hepatic trisectionectomy for colorectal liver metastasis. (Ziff O, Rajput I, Adair R, Toogood GJ, Prasad KR, Lodge JP) HPB (Oxford) 2014 Mar;16(3):212-9 8 Citations |
| 1 | ACR Appropriateness Criteria® management of locoregionally advanced squamous cell carcinoma of the vulva. (Expert Panel on Radiation Oncology-Gynecology, Kidd E, Moore D, Varia MA, Gaffney DK, Elshaikh MA, Erickson B, Jhingran A, Lee LJ, Mayr NA, Puthawala AA, Rao GG, Small W Jr, Wahl AO, Wolfson AH, Yashar CM, Yuh W, Cardenes HR) Am J Clin Oncol 2013 Aug;36(4):415-22 17 Citations |
| 5 | Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. (Bedi M, King DM, Shivakoti M, Wang T, Zambrano EV, Charlson J, Hackbarth D, Neilson J, Whitfield R, Wang D) Radiat Oncol 2013 Mar 14;8:60 23 Citations |
| 1 | The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. (Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB) Ann Surg Oncol 2013 Dec;20 Suppl 3:S500-8 61 Citations |
| 1 | Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. (Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC) Ann Surg Oncol 2013 Apr;20(4):1230-9 10 Citations |
| 1 | Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. (Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL) Nat Med 2012 Jul;18(7):1052-9 227 Citations |
| 1 | Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. (Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Wilson LD, Choy H) Int J Radiat Oncol Biol Phys 2012 Oct 01;84(2):456-63 91 Citations |
| 1 | Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. (Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F) HPB (Oxford) 2012 May;14(5):325-32 15 Citations |
| 1 | Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. (Aadam AA, Evans DB, Khan A, Oh Y, Dua K) Gastrointest Endosc 2012 Jul;76(1):67-75 91 Citations |
| 1 | Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. (Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV) Blood 2012 May 10;119(19):4375-82 406 Citations |
| 1 | Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. (de la Fuente SG, Ludwig KA, Tyler DS, Mantyh CR) Ann Surg Oncol 2012 Jun;19(6):1954-8 2 Citations |
| 1 | Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. (Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H) Cancer 2012 Aug 01;118(15):3801-11 60 Citations |
| 2 | Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 68 Citations |
| 1 | Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. (Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H) Cancer 2012 Jan 01;118(1):268-77 76 Citations |
| 1 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. (Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL) Clin Cancer Res 2011 Apr 01;17(7):2024-34 85 Citations |
| 1 | Impact of neoadjuvant chemotherapy on breast reconstruction. (Hu YY, Weeks CM, In H, Dodgion CM, Golshan M, Chun YS, Hassett MJ, Corso KA, Gu X, Lipsitz SR, Greenberg CC) Cancer 2011 Jul 01;117(13):2833-41 44 Citations |
| 2 | Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. (Evans DB, Erickson BA, Ritch P) Ann Surg Oncol 2010 Nov;17(11):2803-5 61 Citations |
| 1 | International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. (Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, Heriot AG, Leblanc F, Delaney CP, International Rectal Cancer Study Group (IRCSG)) World J Surg 2010 Nov;34(11):2689-700 87 Citations |
| 2 | Portal vein resection. (Christians KK, Lal A, Pappas S, Quebbeman E, Evans DB) Surg Clin North Am 2010 Apr;90(2):309-22 40 Citations |
| 1 | Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. (Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB) Ann Surg Oncol 2010 Jul;17(7):1794-801 137 Citations |
| 2 | Management of borderline resectable pancreatic cancer. (Lal A, Christians K, Evans DB) Surg Oncol Clin N Am 2010 Apr;19(2):359-70 9 Citations |
| 1 | Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. (Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D) J Clin Oncol 2009 Apr 01;27(10):1592-9 47 Citations |
| 1 | Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. (Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2009 Apr;16(4):836-47 430 Citations |
| 1 | Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. (Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, Tawfik O, Holzbeierlein J) J Urol 2009 Feb;181(2):615-9; discussion 619-20 24 Citations |
| 1 | Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. (Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML) Ann Surg Oncol 2009 Feb;16(2):431-9 47 Citations |
| 1 | Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. (de la Fuente SG, Manson RJ, Ludwig KA, Mantyh CR) J Gastrointest Surg 2009 Feb;13(2):269-74 56 Citations |
| 1 | Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB) J Clin Oncol 2008 Jul 20;26(21):3487-95 428 Citations |
| 1 | Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA) J Clin Oncol 2008 Jul 20;26(21):3496-502 672 Citations |
| 1 | Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. (Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF) J Am Coll Surg 2008 May;206(5):833-46; discussion 846-8 730 Citations |
| 1 | A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study. (Malik HZ, Farid S, Al-Mukthar A, Anthoney A, Toogood GJ, Lodge JP, Prasad KR) Ann Surg Oncol 2007 Dec;14(12):3519-26 26 Citations |
| 1 | Future chemoradiation strategies in pancreatic cancer. (Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA) Semin Oncol 2007 Aug;34(4):335-46 29 Citations |
| 1 | Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H) Blood 2007 Nov 15;110(10):3547-51 73 Citations |
| 1 | Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. (Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M) Pediatr Blood Cancer 2007 Aug;49(2):196-8 26 Citations |
| 1 | Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). (Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM) Breast J 2007;13(1):72-5 24 Citations |
| 1 | The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB) Best Pract Res Clin Gastroenterol 2006 Apr;20(2):365-82 46 Citations |
| 1 | Preoperative chemoradiation for pancreatic cancer. (Evans DB) Semin Oncol 2005 Dec;32(6 Suppl 9):S25-9 14 Citations |
| 1 | Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. (Wright JD, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, Gibb RK, Powell MA, Gao F, Siegel BA, Grigsby PW) Cancer 2005 Dec 01;104(11):2484-91 156 Citations |
| 1 | Neoadjuvant therapy for resectable pancreatic cancer. (Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA) Surg Oncol Clin N Am 2004 Oct;13(4):639-61, ix 55 Citations |
| 1 | Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. (Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF) J Clin Oncol 2002 Aug 15;20(16):3445-53 136 Citations |
| 1 | Therapeutic options and treatment of muscle invasive bladder cancer. (O'Connor RC, Alsikafi NF, Steinberg GD) Expert Rev Anticancer Ther 2001 Dec;1(4):511-22 8 Citations |
| 1 | Multimodality management of localized pancreatic cancer. (Wayne JD, Wolff RA, Pisters PW, Evans DB) Cancer J 2001;7 Suppl 1:S35-46 14 Citations |
| 1 | Preoperative chemoradiation therapy for pancreatic cancer. (Evans DB, Pisters PW) Surg Clin North Am 2001 Jun;81(3):709-13 3 Citations |
| 1 | Neoadjuvant strategies for pancreatic cancer. (Evans DB, Wolff RA, Crane CH) Oncology (Williston Park) 2001 Jun;15(6):727-37; discussion 741-4, 747 13 Citations |
| 1 | Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. (Evans DB) J Gastrointest Surg 2001;5(1):2-5 19 Citations |
| 1 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB) J Clin Oncol 2000 Feb;18(4):860-7 82 Citations |
| 1 | Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. (Bold RJ, Charnsangavej C, Cleary KR, Jennings M, Madray A, Leach SD, Abbruzzese JL, Pisters PW, Lee JE, Evans DB) J Gastrointest Surg 1999;3(3):233-43 114 Citations |
| 1 | Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (Breslin TM, Janjan NA, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Evans DB) Front Biosci 1998 Nov 01;3:E193-203 22 Citations |
